Table 1.
Baseline characteristics of the study population.
| Characteristic | Control Group (Sorafenib + Placebo) (n = 16) |
Experimental Group (Sorafenib + Pravastatin) (n = 15) |
Total (n = 31) |
|---|---|---|---|
| Age (years) | 59.94 ± 12.57 | 63.00 ± 10.39 | 61.42 ± 11.48 |
| Sex (M/F) | 14 (87.5%)/2 (12.5%) | 15 (100%)/0 (0%) | 29 (93.5%)/2 (6.5%) |
| Albumin (g/L) | 37.32 ± 8.38 | 40.33 ± 4.59 | 38.83 ± 6.82 |
| Prothrombin activity (INR) | 1.24 ± 0.39 | 1.07 ± 0.10 | 1.16 ± 0.30 |
| Platelets (103/μL) | 180.62 ± 81.38 | 127.53 ± 64.90 | 154.93 ± 77.49 |
| Total bilirubin ≤1.2 mg/dL >1.2 mg/dL Missing |
1.07 ± 0.59 11 (68.8%) 4 (25.0%) 1 (6.2%) |
1.24 ± 0.70 8 (53.3%) 7 (46.7%) 0 (0.0%) |
1.16 ± 0.64 19 (61.3%) 11 (35.5%) 1 (3.2%) |
| Serum AFP ≤100 IU/mL >100 IU/mL Missing |
2710.18 ± 4093.59 6 (37.5%) 8 (50.0%) 2 (12.5%) |
1315.08 ± 3584.00 10 (66.7%) 4 (26.7%) 1 (6.6%) |
2012.63 ± 3841.57 16 (51.6%) 12 (38.7%) 3 (9.7%) |
| Child-Pugh classification: Stage A Stage B |
13 (81.2%) 3 (18.8%) |
15 (100.0%) 0 (0.0%) |
28 (90.3%) 3 (9.7%) |
| ECOG-PS: Grade 0 Grade 1 |
12 (75.0%) 4 (25.0%) |
12 (80.0%) 3 (20.0%) |
24 (77.4%) 7 (22.6%) |
| Portal thrombosis (Yes/No) | 6 (37.5%)/10 (62.5%) | 5 (33.3%)/10 (66.7%) | 11 (35.48%)/20 (64.5%) |
| Vascular invasion (Yes/No) | 8 (50.0%)/8 (50.0%) | 5 (33.3%)/10 (66.7%) | 13 (41.9%)/18 (58.1%) |
| Extrahepatic metastases (Yes/No) | 6 (37.5%)/10 (62.5%) | 6 (40.0%)/9 (60.0%) | 12 (38.7%)/19 (61.3%) |
Continuous variables presented as mean value ± SD; categorical variables presented as absolute frequency and percentage.